Japanese Pharmaceutical Market: Sector Insights

One of the latest market intelligence forecasts for the Japanese Pharmaceutical market from life science commercial intelligence firm Evaluate highlights both negative and positive components affecting future performance, predicting a growth rate of 3.3% (CAGR) between 2017 -2022, significantly lower than Worldwide outlook (6.5% CAGR).

According to the industry analyst the enforcement of a much more stringent pricing revision policy in Japan, both for new products as well as off-patent brands, is behind the decline of the products currently on the market which are forecast to drop about 2% annually in sales through 2022.

The prices of Gilead’s hepatitis C virus (HCV) blockbusters Sovaldi and Harvoni have been subject to significant price scrutiny and most recently the Japanese government has forced a price reduction of 50% on Opdivo, BMS’ novel PD-1/PD-L1 agent.

However, the sales decline of marketed products is counterbalanced by the optimism surrounding new therapies coming to market expected to account for 34% of sales in 2022, among the top ranking are Dupixent (Sanofi), Ibrance (Pfizer), Entresto (Novartis), Aducanumab (Biogen), and Emicizumab (Chugai).

For more information on consensus drug forecasts for the Japanese Pharma and Biotech sector visit www.evaluate.com